Jubilant Pharmova

Jubilant Pharmova Limited is an integrated global pharmaceutical firm engaged in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Generics, and Proprietary Novel Drugs businesses. Relying on strategic planning and disciplined execution, the company confidently navigates the pharmaceutical landscape to drive growth and success in global markets. The company believes in delivering its promise of 'Caring, Sharing, and Growing,' enhancing value for customers and stakeholders through innovation and wise investment. A key business involves manufacturing and supplying Radiopharmaceuticals through a network of 46 radiopharmacies located across the United States. Its Allergy Immunotherapy business manufactures and supplies allergic extracts and venom products to the US and other key markets like Canada, Europe, and Australia. In fiscal year 2024, the company's consolidated revenue from operations grew by 7% to ₹67,029 million, with EBITDA increasing by 20% to ₹9,936 million.;